Growth of the sector also depends on greater recognition of obesity as a chronic disease rather than a consequence of lifestyle choices. Then physicians and policymakers will see the need to treat obesity directly as the root cause of many serious illnesses. Similarly, patients may be more likely to talk to their physicians about the need to treat obesity as drugs become available.
Currently, although more than 650 million people worldwide are clinically obese, only about 7% are diagnosed and recommended for treatment. By comparison, for other chronic diseases such as diabetes, the treatment rate is 80% to 90%.
Purcell and colleagues believe that by 2035, 25 percent of patients classified as obese will use medicine to actively manage their weight.
In addition to the availability of new drugs, policies to make them accessible should also increase both the number of people seeking treatment and the number of doctors prescribing them. In the U.S., for example, policy efforts include a bipartisan effort to expand Medicare coverage for screening and treatment of obesity with FDA-approved drugs from various health care providers who specialize in treating obesity.
As the market for obesity and weight control drugs develops, investors should look to existing large pharmaceutical companies where new drugs are being tested, as well as other large pharmaceutical companies with approved treatments for cardiometabolic diseases, as these companies may seek to develop their own weight control drugs.
More news
What Are Non-Stimulant Fat Burners?
A non-stim fat-burner supplement contains all the beneficial pre-workout ingredients 👍
such as cayenne pepper extracts and green tea extracts, but none of the caffeine or other stimulants